Mergers & Acquisitions ·
Caribou plans to explore strategic alternatives and discontinue CAR-T programs with $15M-$19M restructuring costs
CRBUCaribou Biosciences, Inc.
The Board of Directors approved a process to evaluate strategic alternatives, including potential mergers or acquisitions, while discontinuing development of allogeneic CAR-T therapies vispa-cel and CB-011. The company will implement a substantial workforce reduction expected mostly in Q4 2026 and incur restructuring expenses estimated at $15 million to $19 million. Cash and equivalents stood at $113.8 million as of June 30, 2026. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company.